Niiza, Japan

Tetsuaki Yamura

This inventor holds 1 USPTO granted patent. Top assignee: Fujirebio Kabushiki Kaisha. Active years: 1990.


% Patents Active = 100.0

Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 1990

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Tetsuaki Yamura: Innovator in Anti-Peptic Compounds

Introduction

Tetsuaki Yamura is a notable inventor based in Niiza, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that serve as anti-peptic ulcer agents. His innovative work has led to the creation of valuable intermediates that are essential in the synthesis of therapeutic agents.

Latest Patents

Tetsuaki Yamura holds a patent for "Intermediates for pyridyloxy compounds having utility as anti-peptic." This patent includes compounds that are useful intermediates in producing pyridyloxy derivatives, such as N-{4-[4-(piperidinomethyl)pyridyl-2-oxy]-2-butenyl}-2-(furfurylt hio)acetamide. These compounds are designed to combat peptic ulcers, showcasing the practical applications of his research.

Career Highlights

Yamura is associated with Fujirebio Kabushiki Kaisha, where he has been instrumental in advancing research in pharmaceutical compounds. His work has not only contributed to the company's portfolio but has also had a broader impact on the field of medicinal chemistry.

Collaborations

Tetsuaki Yamura has collaborated with notable colleagues, including Nobuhiko Hirakawa and Noriaki Kashiwaba. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Tetsuaki Yamura's contributions to the field of anti-peptic compounds highlight his role as a significant inventor in medicinal chemistry. His innovative work continues to influence the development of therapeutic agents that improve health outcomes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…